Glycolysis: an early marker for vancomycin-specific T-cell activation
Glycolysis: an early marker for vancomycin-specific T-cell activation
Background: vancomycin, a glycopeptide antibiotic used for Gram-positive bacterial infections, has been linked with drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-A*32:01-expressing individuals. This is associated with activation of T lymphocytes, for which glycolysis has been isolated as a fuel pathway following antigenic stimulation. However, the metabolic processes that underpin drug-reactive T-cell activation are currently undefined and may shed light on the energetic conditions needed for the elicitation of drug hypersensitivity or tolerogenic pathways. Here, we sought to characterise the immunological and metabolic pathways involved in drug-specific T-cell activation within the context of DRESS pathogenesis using vancomycin as model compound and drug-reactive T-cell clones (TCCs) generated from healthy donors and vancomycin-hypersensitive patients.
Methods: CD4+ and CD8+ vancomycin-responsive TCCs were generated by serial dilution. The Seahorse XFe 96 Analyzer was used to measure the extracellular acidification rate (ECAR) as an indicator of glycolytic function. Additionally, T-cell proliferation and cytokine release (IFN-γ) assay were utilised to correlate the bioenergetic characteristics of T-cell activation with in vitro assays.
Results: model T-cell stimulants induced non-specific T-cell activation, characterised by immediate augmentation of ECAR and rate of ATP production (JATPglyc). There was a dose-dependent and drug-specific glycolytic shift when vancomycin-reactive TCCs were exposed to the drug. Vancomycin-reactive TCCs did not exhibit T-cell cross-reactivity with structurally similar compounds within proliferative and cytokine readouts. However, cross-reactivity was observed when analysing energetic responses; TCCs with prior specificity for vancomycin were also found to exhibit glycolytic switching after exposure to teicoplanin. Glycolytic activation of TCC was HLA restricted, as exposure to HLA blockade attenuated the glycolytic induction.
Conclusion: these studies describe the glycolytic shift of CD4+ and CD8+ T cells following vancomycin exposure. Since similar glycolytic switching is observed with teicoplanin, which did not activate T cells, it is possible the master switch for T-cell activation is located upstream of metabolic signalling.
CD8-Positive T-Lymphocytes, Cytokines, Glycolysis, Humans, Lymphocyte Activation, Teicoplanin, Vancomycin/adverse effects, T lymphocytes, DRESS, glycolysis, vancomycin, drug hypersensitivity
21-33
Gardner, Joshua
f702f23e-1bc8-46a2-ba5d-375acce77d82
Hammond, Sean
09e0adb8-628f-4ae2-abb5-e15bd897cc91
Jensen, Rebecca
27805377-c32e-4c19-b6d7-82f46e2c4770
Gibson, Andrew
8e4893ca-e598-4b4b-945a-67a3ca1e8024
Krantz, Matthew S.
2d602a0e-3a8e-4ab9-8d72-6b8dd960c2e1
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90
Phillips, Elizabeth J.
90b66345-c590-47e1-aa29-0d41b60bb998
Pirmohamed, Munir
63cc7367-4b1c-49a8-8ee4-66ab035a8259
Chadwick, Amy E.
713f28e5-db31-4649-a3fd-a608cdef5527
Betts, Catherine
92b03bbb-f807-4e57-ba0a-25bfa55aa93a
Naisbitt, Dean J.
9f21cc6e-dc59-4e20-88fa-cffe4204f8df
January 2024
Gardner, Joshua
f702f23e-1bc8-46a2-ba5d-375acce77d82
Hammond, Sean
09e0adb8-628f-4ae2-abb5-e15bd897cc91
Jensen, Rebecca
27805377-c32e-4c19-b6d7-82f46e2c4770
Gibson, Andrew
8e4893ca-e598-4b4b-945a-67a3ca1e8024
Krantz, Matthew S.
2d602a0e-3a8e-4ab9-8d72-6b8dd960c2e1
Ardern-Jones, Michael
7ac43c24-94ab-4d19-ba69-afaa546bec90
Phillips, Elizabeth J.
90b66345-c590-47e1-aa29-0d41b60bb998
Pirmohamed, Munir
63cc7367-4b1c-49a8-8ee4-66ab035a8259
Chadwick, Amy E.
713f28e5-db31-4649-a3fd-a608cdef5527
Betts, Catherine
92b03bbb-f807-4e57-ba0a-25bfa55aa93a
Naisbitt, Dean J.
9f21cc6e-dc59-4e20-88fa-cffe4204f8df
Gardner, Joshua, Hammond, Sean, Jensen, Rebecca, Gibson, Andrew, Krantz, Matthew S., Ardern-Jones, Michael, Phillips, Elizabeth J., Pirmohamed, Munir, Chadwick, Amy E., Betts, Catherine and Naisbitt, Dean J.
(2024)
Glycolysis: an early marker for vancomycin-specific T-cell activation.
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 54 (1), .
(doi:10.1111/cea.14423).
Abstract
Background: vancomycin, a glycopeptide antibiotic used for Gram-positive bacterial infections, has been linked with drug reaction with eosinophilia and systemic symptoms (DRESS) in HLA-A*32:01-expressing individuals. This is associated with activation of T lymphocytes, for which glycolysis has been isolated as a fuel pathway following antigenic stimulation. However, the metabolic processes that underpin drug-reactive T-cell activation are currently undefined and may shed light on the energetic conditions needed for the elicitation of drug hypersensitivity or tolerogenic pathways. Here, we sought to characterise the immunological and metabolic pathways involved in drug-specific T-cell activation within the context of DRESS pathogenesis using vancomycin as model compound and drug-reactive T-cell clones (TCCs) generated from healthy donors and vancomycin-hypersensitive patients.
Methods: CD4+ and CD8+ vancomycin-responsive TCCs were generated by serial dilution. The Seahorse XFe 96 Analyzer was used to measure the extracellular acidification rate (ECAR) as an indicator of glycolytic function. Additionally, T-cell proliferation and cytokine release (IFN-γ) assay were utilised to correlate the bioenergetic characteristics of T-cell activation with in vitro assays.
Results: model T-cell stimulants induced non-specific T-cell activation, characterised by immediate augmentation of ECAR and rate of ATP production (JATPglyc). There was a dose-dependent and drug-specific glycolytic shift when vancomycin-reactive TCCs were exposed to the drug. Vancomycin-reactive TCCs did not exhibit T-cell cross-reactivity with structurally similar compounds within proliferative and cytokine readouts. However, cross-reactivity was observed when analysing energetic responses; TCCs with prior specificity for vancomycin were also found to exhibit glycolytic switching after exposure to teicoplanin. Glycolytic activation of TCC was HLA restricted, as exposure to HLA blockade attenuated the glycolytic induction.
Conclusion: these studies describe the glycolytic shift of CD4+ and CD8+ T cells following vancomycin exposure. Since similar glycolytic switching is observed with teicoplanin, which did not activate T cells, it is possible the master switch for T-cell activation is located upstream of metabolic signalling.
Text
Clin Experimental Allergy - 2024 - Gardner - Glycolysis An early marker for vancomycin‐specific T‐cell activation
- Version of Record
More information
Accepted/In Press date: 1 November 2023
e-pub ahead of print date: 4 January 2024
Published date: January 2024
Additional Information:
Publisher Copyright:
© 2024 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Keywords:
CD8-Positive T-Lymphocytes, Cytokines, Glycolysis, Humans, Lymphocyte Activation, Teicoplanin, Vancomycin/adverse effects, T lymphocytes, DRESS, glycolysis, vancomycin, drug hypersensitivity
Identifiers
Local EPrints ID: 490406
URI: http://eprints.soton.ac.uk/id/eprint/490406
ISSN: 0954-7894
PURE UUID: 8b94c00f-759c-45c1-9b54-188f5da8886f
Catalogue record
Date deposited: 24 May 2024 16:56
Last modified: 11 Jun 2024 01:41
Export record
Altmetrics
Contributors
Author:
Joshua Gardner
Author:
Sean Hammond
Author:
Rebecca Jensen
Author:
Andrew Gibson
Author:
Matthew S. Krantz
Author:
Elizabeth J. Phillips
Author:
Munir Pirmohamed
Author:
Amy E. Chadwick
Author:
Catherine Betts
Author:
Dean J. Naisbitt
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics